<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We have previously reported evidence of an inverse association between a urinary F(2)-isoprostane and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> risk in a pilot case-control study nested within the <z:hpo ids='HP_0000855'>Insulin Resistance</z:hpo> <z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> Study (IRAS) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report the results from the study extended to the entire IRAS cohort </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: This prospective study included 138 incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> case and 714 noncase subjects </plain></SENT>
<SENT sid="3" pm="."><plain>Four F(2)-isoprostanes (iPF2α-III; 2,3-dinor-iPF2α-III; iPF2α-VI; and 8,12-iso-iPF2α-VI) were assayed in baseline urine samples using liquid chromatography-tandem mass spectrometry </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Three F(2)-isoprostanes showed significant inverse associations with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> risk: the adjusted odds ratios were 0.52 (95% CI 0.39-0.67), 0.56 (0.42-0.73), 0.62 (0.48-0.79), and 0.91 (0.72-1.12) for iPF2α-III; 2,3-dinor-iPF2α-III; iPF2α-VI; and 8,12-iso-iPF2α-VI, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Our findings indicate that urinary F(2)-isoprostanes are inversely associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> risk beyond the traditional risk factors and may be useful in identifying high-risk populations </plain></SENT>
</text></document>